China Approves Additional Remimazolam Indication for Jiangsu Hengrui
China’s NMPA approved an additional indication for Jiangsu Hengrui’s remimazolam tosylate for injection.
Related stories
Amazon, Uber and Instacart Sue to Block NYC Delivery Worker Law
The companies sued to block a New York City law concerning delivery worker deactivation.
M impact | REGULATION | Oct 29, 2026, 03:33 PM UTC
IMF Aims to Clear Egypt Program Review by Mid-December
L impact | REGULATION | Oct 29, 2026, 03:27 PM UTC
FCC Votes to Ban Chinese Labs From Testing US Electronics
The FCC voted to prohibit Chinese labs from testing electronics for the US market.
M impact | REGULATION | Oct 29, 2026, 03:26 PM UTC
UK Orders Crypto Exchange HTX to Stop Doing Business
UK authorities ordered crypto exchange HTX to stop doing business in the country.
M impact | REGULATION | Oct 29, 2026, 03:22 PM UTC
NLRB dismisses lawsuit over Tesla workplace IT policy
The U.S. National Labor Relations Board dismissed a lawsuit concerning Tesla’s workplace IT policy.
L impact | REGULATION | Oct 29, 2026, 03:21 PM UTC
US Labor Board Dismisses Tesla Workplace IT Policy Complaint
The National Labor Relations Board dismissed a complaint concerning Tesla’s workplace IT policy.
L impact | REGULATION | Oct 29, 2026, 03:21 PM UTC